MersV1, Istex, Checkpoint, bibRecord, 000F88

Synthetic peptides that inhibit binding of the collagen type II 261–273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses

Identifieur interne : 000F88 ( Istex/Checkpoint ); précédent : 000F87; suivant : 000F89

Synthetic peptides that inhibit binding of the collagen type II 261–273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses

Auteurs : Masha Fridkis-Hareli ; Edward F. Rosloniec ; Lars Fugger ; Jack L. Strominger [États-Unis]

Source :

Human Immunology [ 0198-8859 ] ; 2000.

RBID : ISTEX:4A688E64C500D391433145EBE69E392ACC9F023B

English descriptors

KwdEn :
- CII, Cop 1, HLA-DR molecules, MS, RA, antigen presentation, rheumatoid arthritis, synthetic peptides.
Teeft :
- Amino, Amino acids, Antigen presentation, Arnon, Arthritis, Arthritis rheum, Assay, Autoimmune, Binding motifs, Biotinylated, Cell clones, Cell response, Cells transfected, Clone, Collagen type, Competitive binding assays, Copolymer, Crystal structure, Encephalomyelitis, Epitope, Histocompatibility, Human class, Hybridoma, Immunodominant epitope, Immunol, Independent experiments, Inhibitor, Methods section, Molecule, Multiple sclerosis, Peptide, Peptide binding, Poly, Proc natl acad, Random polypeptides, Rheumatoid, Rheumatoid arthritis, Rothbard, Sclerosis, Sela, Side chains, Strominger, Synthetic peptides, Teitelbaum, Transfected, Transgenic mice.

Abstract

Abstract: Copolymer 1 [Cop 1, poly (Y, E, A, K)] is a random synthetic amino acid copolymer effective in the treatment of relapsing forms of multiple sclerosis (MS), a disease that is linked to HLA-DR2 (DRB1∗1501). Another copolymer [poly (Y, A, K)] was also identified that binds to rheumatoid arthritis (RA)-associated HLA-DR1 (DRB1∗0101) or HLA-DR4 (DRB1∗0401) molecules and inhibits the response of HLA-DR1- and -DR4-restricted T cell clones to an immunodominant epitope of collagen type II (CII) 261–273 (a candidate autoantigen in RA). In the present study various peptides have been synthesized based on binding “motifs” of Cop 1 for HLA-DR1 and -DR4 molecules. Those peptides with K at P-1 or K at P8 were particularly effective as inhibitors of binding of CII 261–273, of Cop 1 and of the influenza virus hemagglutinin peptide 306–318 to these class II proteins. Moreover, several of them were also potent inhibitors of the CII 261–273-reactive T cell clones. These findings suggest that small peptides or their more stable derivatives may be able to substitute for copolymers in the treatment of RA, and by implication of MS.

Url:

https://api.istex.fr/ark:/67375/6H6-7CBX3HVL-K/fulltext.pdf

DOI: 10.1016/S0198-8859(00)00126-9

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 000806
to stream Istex, to step Curation: 000806

Links to Exploration step

ISTEX:4A688E64C500D391433145EBE69E392ACC9F023B

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Synthetic peptides that inhibit binding of the collagen type II 261–273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses</title>
<author><name sortKey="Fridkis Hareli, Masha" sort="Fridkis Hareli, Masha" uniqKey="Fridkis Hareli M" first="Masha" last="Fridkis-Hareli">Masha Fridkis-Hareli</name>
</author>
<author><name sortKey="Rosloniec, Edward F" sort="Rosloniec, Edward F" uniqKey="Rosloniec E" first="Edward F" last="Rosloniec">Edward F. Rosloniec</name>
</author>
<author><name sortKey="Fugger, Lars" sort="Fugger, Lars" uniqKey="Fugger L" first="Lars" last="Fugger">Lars Fugger</name>
</author>
<author><name sortKey="Strominger, Jack L" sort="Strominger, Jack L" uniqKey="Strominger J" first="Jack L" last="Strominger">Jack L. Strominger</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:4A688E64C500D391433145EBE69E392ACC9F023B</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1016/S0198-8859(00)00126-9</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-7CBX3HVL-K/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000806</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000806</idno>
<idno type="wicri:Area/Istex/Curation">000806</idno>
<idno type="wicri:Area/Istex/Checkpoint">000F88</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000F88</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Synthetic peptides that inhibit binding of the collagen type II 261–273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses</title>
<author><name sortKey="Fridkis Hareli, Masha" sort="Fridkis Hareli, Masha" uniqKey="Fridkis Hareli M" first="Masha" last="Fridkis-Hareli">Masha Fridkis-Hareli</name>
<affiliation><wicri:noCountry code="subField">(L.F.)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Rosloniec, Edward F" sort="Rosloniec, Edward F" uniqKey="Rosloniec E" first="Edward F" last="Rosloniec">Edward F. Rosloniec</name>
<affiliation><wicri:noCountry code="subField">(E.F.R.)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Fugger, Lars" sort="Fugger, Lars" uniqKey="Fugger L" first="Lars" last="Fugger">Lars Fugger</name>
<affiliation><wicri:noCountry code="subField">(L.F.)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Strominger, Jack L" sort="Strominger, Jack L" uniqKey="Strominger J" first="Jack L" last="Strominger">Jack L. Strominger</name>
<affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country>
</affiliation>
<affiliation wicri:level="4"><orgName type="university">Université Harvard</orgName>
<country>États-Unis</country>
<placeName><settlement type="city">Cambridge (Massachusetts)</settlement>
<region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Human Immunology</title>
<title level="j" type="abbrev">HIM</title>
<idno type="ISSN">0198-8859</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="2000">2000</date>
<biblScope unit="volume">61</biblScope>
<biblScope unit="issue">7</biblScope>
<biblScope unit="page" from="640">640</biblScope>
<biblScope unit="page" to="650">650</biblScope>
</imprint>
<idno type="ISSN">0198-8859</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0198-8859</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>CII</term>
<term>Cop 1</term>
<term>HLA-DR molecules</term>
<term>MS</term>
<term>RA</term>
<term>antigen presentation</term>
<term>rheumatoid arthritis</term>
<term>synthetic peptides</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Amino</term>
<term>Amino acids</term>
<term>Antigen presentation</term>
<term>Arnon</term>
<term>Arthritis</term>
<term>Arthritis rheum</term>
<term>Assay</term>
<term>Autoimmune</term>
<term>Binding motifs</term>
<term>Biotinylated</term>
<term>Cell clones</term>
<term>Cell response</term>
<term>Cells transfected</term>
<term>Clone</term>
<term>Collagen type</term>
<term>Competitive binding assays</term>
<term>Copolymer</term>
<term>Crystal structure</term>
<term>Encephalomyelitis</term>
<term>Epitope</term>
<term>Histocompatibility</term>
<term>Human class</term>
<term>Hybridoma</term>
<term>Immunodominant epitope</term>
<term>Immunol</term>
<term>Independent experiments</term>
<term>Inhibitor</term>
<term>Methods section</term>
<term>Molecule</term>
<term>Multiple sclerosis</term>
<term>Peptide</term>
<term>Peptide binding</term>
<term>Poly</term>
<term>Proc natl acad</term>
<term>Random polypeptides</term>
<term>Rheumatoid</term>
<term>Rheumatoid arthritis</term>
<term>Rothbard</term>
<term>Sclerosis</term>
<term>Sela</term>
<term>Side chains</term>
<term>Strominger</term>
<term>Synthetic peptides</term>
<term>Teitelbaum</term>
<term>Transfected</term>
<term>Transgenic mice</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: Copolymer 1 [Cop 1, poly (Y, E, A, K)] is a random synthetic amino acid copolymer effective in the treatment of relapsing forms of multiple sclerosis (MS), a disease that is linked to HLA-DR2 (DRB1∗1501). Another copolymer [poly (Y, A, K)] was also identified that binds to rheumatoid arthritis (RA)-associated HLA-DR1 (DRB1∗0101) or HLA-DR4 (DRB1∗0401) molecules and inhibits the response of HLA-DR1- and -DR4-restricted T cell clones to an immunodominant epitope of collagen type II (CII) 261–273 (a candidate autoantigen in RA). In the present study various peptides have been synthesized based on binding “motifs” of Cop 1 for HLA-DR1 and -DR4 molecules. Those peptides with K at P-1 or K at P8 were particularly effective as inhibitors of binding of CII 261–273, of Cop 1 and of the influenza virus hemagglutinin peptide 306–318 to these class II proteins. Moreover, several of them were also potent inhibitors of the CII 261–273-reactive T cell clones. These findings suggest that small peptides or their more stable derivatives may be able to substitute for copolymers in the treatment of RA, and by implication of MS.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Massachusetts</li>
</region>
<settlement><li>Cambridge (Massachusetts)</li>
</settlement>
<orgName><li>Université Harvard</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Fridkis Hareli, Masha" sort="Fridkis Hareli, Masha" uniqKey="Fridkis Hareli M" first="Masha" last="Fridkis-Hareli">Masha Fridkis-Hareli</name>
<name sortKey="Fugger, Lars" sort="Fugger, Lars" uniqKey="Fugger L" first="Lars" last="Fugger">Lars Fugger</name>
<name sortKey="Rosloniec, Edward F" sort="Rosloniec, Edward F" uniqKey="Rosloniec E" first="Edward F" last="Rosloniec">Edward F. Rosloniec</name>
</noCountry>
<country name="États-Unis"><noRegion><name sortKey="Strominger, Jack L" sort="Strominger, Jack L" uniqKey="Strominger J" first="Jack L" last="Strominger">Jack L. Strominger</name>
</noRegion>
<name sortKey="Strominger, Jack L" sort="Strominger, Jack L" uniqKey="Strominger J" first="Jack L" last="Strominger">Jack L. Strominger</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F88 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd -nk 000F88 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Istex
   |étape=   Checkpoint
   |type=    RBID
   |clé=     ISTEX:4A688E64C500D391433145EBE69E392ACC9F023B
   |texte=   Synthetic peptides that inhibit binding of the collagen type II 261–273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses
}}

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Synthetic peptides that inhibit binding of the collagen type II 261–273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses

Synthetic peptides that inhibit binding of the collagen type II 261–273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri